St. Jude Medical announced publication of results from its landmark RESPECT clinical trial in The New England Journal of Medicine.

 

Minimally invasive procedures significantly lower health payer costs and result in fewer missed workdays when compared to open surgery, according to a study published this week in the Journal of the American Medical Association (JAMA) Surgery. Of six procedures examined, the percutaneous coronary intervention (PCI) arm of the study drove the cost savings. This is an important finding, considering that heart disease remains the leading cause of death and disability in the United States and accounts for considerable expenditures in healthcare services, medications and lost productivity.

A new test that detects asymptomatic individuals who may be at risk for cardiovascular disease is being launched in Europe at the Healthcare Innovation Expo 2013. The device, known as AngioDefender, was developed by Everist Genomics Inc. of Ann Arbor, Mich., in collaboration with scientists at Rutgers University, New Jersey. The developers claim that the test will lower the cost of detecting and treating cardiovascular problems and improve patient outcomes.

Biotronik Iforia ICD/CRT-D CE-Approval

Biotronik received CE mark for its most advanced ICD/CRT-D (implantable cardioverter defibrillator/cardiac resynchronization therapy device) series. Iforia is the world’s first DF4 ICD/CRT-D series approved for MRI (magnetic resonance imaging). In addition it contains one of the world’s smallest ICDs, the Iforia single chamber ICD.

The Heart Failure 2013 LA meeting will include a showcase of several startup companies offering innovative new approaches to address heart and cardiovascular disease.

The U.S. Food and Drug Administration (FDA) notified healthcare professionals of a Class I recall of the Vascular Solutions Inc. Guardian II and Guardian II NC Hemostasis Valves. The firm is recalling the product due to a risk that air may be introduced into the device which may lead to an air embolism. This product may cause serious adverse health consequences, including death.

FujiFilm Medical Systems U.S.A. Inc. showcased its Synapse 3D at the American College of Cardiology (ACC) conference March 9 to 11, 2013 at the Moscone Center in San Francisco, Calif. Fully integrated with Synapse Cardiovascular, Synapse 3D will appeal to cardiologists and cardiovascular specialists interested in advanced visualization and analysis for their diagnostic needs.

NeuroVive announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center clinical trial (CIRCUS trial) assessing CicloMulsion (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction.

March 26, 2013 — According to two different reports from Millennium Research Group (MRG), the overall European market for peripheral vascular devices will grow strongly, reaching $1.3 billion by 2017. Increases in endovascular procedures, along with innovations such as drug-coated balloons (DCB), aortic stent grafts and chronic total occlusion (CTO) crossing devices, will support revenue growth.

March 26, 2013 — A multicenter analysis, led by Weill Cornell Medical College and published in the Journal of Clinical Gastroenterology, shows the use of temporary "fully covered self-expanding metal stents" (FCSEMS) can effectively fix a painful and potentially life-threatening benign biliary stricture.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now